6ry4
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==PARP15 catalytic domain in complex with 4-(3-carbamoylphenoxy)benzamide.== | ==PARP15 catalytic domain in complex with 4-(3-carbamoylphenoxy)benzamide.== | ||
- | <StructureSection load='6ry4' size='340' side='right'caption='[[6ry4]]' scene=''> | + | <StructureSection load='6ry4' size='340' side='right'caption='[[6ry4]], [[Resolution|resolution]] 1.95Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6RY4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6RY4 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6ry4]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6RY4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6RY4 FirstGlance]. <br> |
- | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ry4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ry4 OCA], [https://pdbe.org/6ry4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ry4 RCSB], [https://www.ebi.ac.uk/pdbsum/6ry4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ry4 ProSAT]</span></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.95Å</td></tr> |
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=KMW:3-(4-aminocarbonylphenoxy)benzamide'>KMW</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ry4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ry4 OCA], [https://pdbe.org/6ry4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ry4 RCSB], [https://www.ebi.ac.uk/pdbsum/6ry4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ry4 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/PAR15_HUMAN PAR15_HUMAN] Transcriptional repressor. Has ADP-ribosyltransferase activity. | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Intracellular ADP-ribosyltransferases catalyze mono- and poly-ADP-ribosylation and affect a broad range of biological processes. The mono-ADP-ribosyltransferase PARP10 is involved in signaling and DNA repair. Previous studies identified OUL35 as a selective, cell permeable inhibitor of PARP10. We have further explored the chemical space of OUL35 by synthesizing and investigating structurally related analogs. Key synthetic steps were metal-catalyzed cross-couplings and functional group modifications. We identified 4-(4-cyanophenoxy)benzamide and 3-(4-carbamoylphenoxy)benzamide as PARP10 inhibitors with distinct selectivities. Both compounds were cell permeable and interfered with PARP10 toxicity. Moreover, both revealed some inhibition of PARP2 but not PARP1, unlike clinically used PARP inhibitors, which typically inhibit both enzymes. Using crystallography and molecular modeling the binding of the compounds to different ADP-ribosyltransferases was explored regarding selectivity. Together, these studies define additional compounds that interfere with PARP10 function and thus expand our repertoire of inhibitors to further optimize selectivity and potency. | ||
+ | |||
+ | Evaluation of 3- and 4-Phenoxybenzamides as Selective Inhibitors of the Mono-ADP-Ribosyltransferase PARP10.,Korn P, Classen A, Murthy S, Guareschi R, Maksimainen MM, Lippok BE, Galera-Prat A, Sowa ST, Voigt C, Rossetti G, Lehtio L, Bolm C, Luscher B ChemistryOpen. 2021 Jun 19. doi: 10.1002/open.202100087. PMID:34145784<ref>PMID:34145784</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
+ | <div class="pdbe-citations 6ry4" style="background-color:#fffaf0;"></div> | ||
+ | |||
+ | ==See Also== | ||
+ | *[[Poly(ADP-ribose) polymerase 3D structures|Poly(ADP-ribose) polymerase 3D structures]] | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
+ | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Lehtio L]] | [[Category: Lehtio L]] | ||
[[Category: Maksimainen MM]] | [[Category: Maksimainen MM]] | ||
[[Category: Murthy SN]] | [[Category: Murthy SN]] |
Revision as of 12:30, 24 January 2024
PARP15 catalytic domain in complex with 4-(3-carbamoylphenoxy)benzamide.
|